OncoMed Pharmaceuticals, Inc. Presents Data From Clinical Trials of Four Novel Anti-Cancer Stem Cell (Anti-CSC) Therapeutics at the American Association for Cancer Research-National Cancer Institute-EORTC International Conference on Molecular Targets and

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif., Oct. 21, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported data for four of its five clinical-stage programs at poster sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19-23, 2013, at the Hynes Convention Center in Boston, MA.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC